Replies to post #255411 on Biotech Values

[dewophile]

I think it would be worth a good amount if the phase 1 data are good. THRD had base data in phase 1 with greater heme toxicity etc. so normal phase 1 genuinely derisks the program
comparable early stage and even preclinnical companies have gotten in the ballpark of 200M for I/I assets along w billion(s) milestones and opt-ins or profit sharing
so yeah i guess do whatever research you want if you want on comps.

[WorstLuck]

ENTA (BPMC)

As an aside, we'll know what the market thinks of the cvr's in the deal when it gets closer to closing and they get fully priced in, so there would be a discount rate to work from.

With the tender set to close next week and BPMC trading around 128.40 (129 + cvr's for tender) it's hard to see any enthusiasm for the CSU cvr's. I haven't seen the HSR yet, which was filed on June 9th, but also nothing from the companies to suggest a delay so.... we'll see how it looks next week.